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Troponin plays a central role in regulation of muscle contraction. It is the Ca2+
switch of striated muscles including the heart and in the cardiac muscle it is
physiologically modulated by PKA-dependent phosphorylation at Ser22 and 23. Many
cardiomyopathy-related mutations affect Ca2+ regulation and/or disrupt the relationship
between Ca2+ binding and phosphorylation. Unlike the mechanism of heart activation,
the modulation of Ca2+-sensitivity by phosphorylation of the cardiac specific N-terminal
segment of TnI (1–30) is structurally subtle and has proven hard to investigate. The crystal
structure of cardiac troponin describes only the relatively stable core of the molecule
and the crucial mobile parts of the molecule are missing including TnI C-terminal region,
TnI (1–30), TnI (134–149) (“inhibitory” peptide) and the C-terminal 28 amino acids of
TnT that are intrinsically disordered. Recent studies have been performed to answer
this matter by building structural models of cardiac troponin in phosphorylated and
dephosphorylated states based on peptide NMR studies. Now these have been updated
bymore recent concepts derived frommolecular dynamic simulations treating troponin as
a dynamic structure. The emerging model confirms the stable core structure of troponin
and the mobile structure of the intrinsically disordered segments. We will discuss how we
can describe these segments in terms of dynamic transitions between a small number
of states, with the probability distributions being altered by phosphorylation and by
HCM or DCM-related mutations that can explain how Ca2+-sensitivity is modulated by
phosphorylation and the effects of mutations.
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INTRODUCTION
Since its discovery by Ebashi and Kodama (1965), troponin has been a molecule that never ceases
to be studied, due to its central role in muscle contraction and regulation. In heart muscle,
troponin has a dual function, both to switch contraction on and off in response to Ca2+ and
to modulate Ca2+-sensitivity and the rate of relaxation in response to adrenaline, a process that
is disrupted in cardiomyopathy (Solaro et al., 2008; Messer and Marston, 2014). To properly
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understand these functions of troponin and the mechanisms
behind them, it is important to establish structure-function
relationships. Recently, cardiac troponin has been recognized
as a “dynamic” molecule, containing intrinsically disordered
regions (Colson et al., 2012; Hwang et al., 2014). We are
particularly interested in these regions, their relationship to
troponin’s function and how they change due to phosphorylation
and mutations. Ultimately, this information can be used for the
treatment of cardiomyopathy, by designing drugs that will target
these dynamic transitions.
THE REGULATION OF CONTRACTION BY
TROPONIN
The early studies on troponin used biochemical and biophysical
methods to measure troponin’s activity switching and identify
protein-protein interactions involved. It soon became apparent
that troponin-regulated thin filaments are a very complex system.
The thin filament is a multiprotein complex with a repeating
unit comprised of 24 proteins [14 actin, 2 tropomyosin dimers,
2 troponin I (TnI), 2 troponin T (TnT), and 2 troponin C
(TnC)]. The troponin molecule complex is shown in Figure 1A.
The thin filament can contain up to 30 such units in a system
that allows Ca2+ binding to TnC to control myosin binding to
actin, allowing contraction (Gordon et al., 2000). As expected
for a switch, the whole system is dynamic and the properties of
the switch are modified by cellular signaling systems, notably
phosphorylation of TnI by PKA. Whilst thin filaments can be
FIGURE 1 | (A) Ribbon diagram of troponin and its different subunits. Blue represents TnC (1–161), red represents TnI (1–171) and green represents TnT (212–298).
Catalytic and structural Ca2+ are shown as gray spheres, and the inhibitory and the switch peptide of TnI are indicated. (B) Snapshot of troponin MD simulation,
showing troponin surface rendering in a solvent box. Blue represents TnC (1–161), red represents TnI (1–171) and green represents TnT (212–298). The image was
adapted from Zamora et al. (2016a) with permission from the PCCP Owner Societies.
described in terms of the protein interactions involved (Farah
and Reinach, 1995), or the transitions between states (Maytum
et al., 1999), a complete structure of the thin filament remains
elusive.
The structure of the actin filament has been solved to
high resolution (Oda et al., 2009), as well as tropomyosin
by X-ray diffraction (Brown et al., 2005) and the complex
of tropomyosin on actin has been accurately deduced from
electron micrographs (Moore et al., 2016). Troponin was the last
component to be solved by crystallography, reflecting both its
heterotrimeric nature and its inherent flexibility (Takeda et al.,
2003; Vinogradova et al., 2005). The troponin crystal structure
is incomplete, however, and does not include some of the most
functionally interesting parts of the complex.
These structural studies suffer from a critical defect: they only
provide structures that are frozen in a particular state that may
or may not correspond to one of the functional states defined
by biochemistry, yet troponin is a highly dynamic molecule
that easily flips between activity states. Current structures do
not resolve several segments of troponin that are potentially
involved in regulation including the inhibitory (138–147) and
switch (148–154) regions of TnI as well as the C-terminal mobile
domain (164–210) and the C-terminal 18 amino acids of TnT.
Thus, for understanding troponin function we need to define the
structure of the wholemolecule and take into account its dynamic
nature. Recent concepts describe that order-disorder transitions
in the dynamic regions of troponin are important for muscle
contraction regulation (Metskas and Rhoades, 2016).
Frontiers in Physiology | www.frontiersin.org 2 November 2016 | Volume 7 | Article 508
Papadaki and Marston The Function of Troponin As a Disordered Molecule
The C-terminal mobile peptide of skeletal TnI was the first
one to be identified as a dynamic peptide on troponin and its
dynamic structure gives kinetic activity advantage for binding
to actin (Blumenschein et al., 2006; Hoffman et al., 2006). The
dynamic segments of cardiac troponin were explicitly defined
by Tobacman using isotope exchange methods (Kowlessur and
Tobacman, 2012), whereas fluorescent anisotropy experiments
on cardiac TnI provided experimental evidence on the existence
of these dynamic domains (Zhou et al., 2012). The dynamic
regions of TnI vary between troponin isoforms, with skeletal
troponin having a higher level of disorder. In addition, cardiac
TnI contains a disordered region absent in the skeletal isoform,
the N-terminal extension containing the phosphorylatable Ser22
and 23 (Hoffman and Sykes, 2008). Phosphorylation at Ser22
and 23 causes a 2-3-fold change in Ca2+-sensitivity, which has
a major physiological impact on cardiac function.
RECENT STUDIES OF CARDIAC
TROPONIN REGULATION
Baryshnikova demonstrated that phosphorylation of TnI Ser22
and 23 modulates the overall affinity of the N-terminal
lobe of TnC to TnI (147–163) rather than the Ca2+-affinity
(Baryshnikova et al., 2008). A study of the interaction of the
native and phosphorylated TnI (1–30) in isolation led to a model
for the differential docking of this peptide on TnC in native and
phosphorylated states (Howarth et al., 2007), but more recently
the question was addressed in a model-free study using whole
TnC and TnI (1–73) (Hwang et al., 2014). TnI (1–37) segment,
described as intrinsically disordered, interacts electrostatically
with the N-terminal lobe of TnC, whilst TnI (41–67) forms a
helix that interacts with a hydrophobic patch in the C-terminal
TnC lobe, as found in the crystal structure. This study proposed
that interactions of TnI (1–30) with the TnC N-terminal lobe
stabilized the position of the N-terminal lobe relative to the
rest of troponin and that this positioning indirectly affects
Ca2+ and TnI (148–158) affinity. Phosphorylation disrupts the
interactions and the loss of positioning leads to changes in
Ca2+-sensitivity. Disorder in proteins is currently studied using
molecular dynamics (MD) simulations in combination with
structural studies, such as NMR.
Molecular dynamics (MD) is a computational technique
whereby proteins can be viewed as moving objects rather than
stable peptides. Thus, intrinsically disordered peptides can be
analyzed in terms of their dynamic, as well as their static
properties. The idea behind MD is to calculate the energy of a
system as a function of the position of its atoms. MD simulations
can help us understand biological functions of proteins, such
as conformational changes caused by interactions with other
proteins or ligands. Additional properties can be measured,
for example flexibility of proteins traditionally measured in
nanosecond (ns) timescales, although biological events happen
within microseconds (µs).
Recent technical developments have applied this
computational method to cardiac troponin. A seminal MD
study simulated Ca2+ binding to the TnC N-terminal domain
over a µs timescale, much longer that commonly used (Lindert
et al., 2012). This simulation showed the dynamics of opening
and closing of the hydrophobic patch upon Ca2+ binding
predicted by NMR studies, whilst also emphasizing the need for
extended simulations to allow time for all possible conformations
to be explored (Lindert et al., 2012). This highlights a central
challenge of MD studies: the immense amount of time and
computing power needed for an extended simulation must be
balanced by the need to obtain results in a meaningful timescale.
Moreover the protein investigated must be placed in a virtual
solvent box big enough to avoid any contacts with the box sides.
The larger the system studied the greater the problems become,
however MD simulations of troponin (about 500,000 atoms
including solvent) have now been carried out by two groups.
Molecular dynamics (MD) simulations of the cardiac troponin
were performed in a study by Cheng et al. (2014). In that
study, the troponin complex structure [TnI (1–172), TnC
(1–161), TnT (236–285)] was modeled and the phosphomimetic
mutations S23D/S24D were introduced to study the effect of
phosphorylation and also the effect of disease-related mutations.
The length of simulation was limited to 3 × 150 ns (Cheng
et al., 2015). The more recent MD simulation study by Zamora
et al provides an even more complete model of human cardiac
troponin sequence (Figure 1B), including the C-terminal peptide
of TnT not present in previous studies. Multiple 750 ns
simulations, totaling over 10µs, were performed and the size
of the box simulated has been increased to 25Å to avoid virtual
self-association (Zamora et al., 2016a).
INSIGHTS FOR TROPONIN REGULATORY
MECHANISM
Recent studies have come to the conclusion that cardiac troponin
contains intrinsically disordered regions, and one of them is the
TnI (1–30), which contains the phosphorylatable Ser22 and 23.
In fact, being disordered is significant for the phosphorylation
itself and it has been found that the majority of proteins that get
phosphorylated in nature have intrinsically disordered domains
close to the phosphorylation site (Iakoucheva et al., 2004).
Using MD simulations to study the effects of mutations or
phosphorylation is therefore a suitable approach, because the
disordered regions are included in the model. MD provides the
opportunity to look at the overall stability of the protein by
calculating the Root Mean Square Fluctuation (RMSF) and any
interaction between the subunits can be measured.
In that respect, it is important to establish which interactions
are relevant to troponin’s function. Both Zamora’s and Cheng’s
MD studies agree that the order-disorder transition associated
with phosphorylation proposed by Hwang et al is unlikely
since both states are disordered. Distances between Ca2+ and
coordinating residues within the Ca2+ binding loop are almost
always measured, because direct comparisons with biochemical
measurements can be made. The MD studies of Cheng and
Zamora indicate that measuring the distances between the TnC
Ser69 gamma Oxygen (GO) and Ca2+ would give information
about the Ca2+-sensitivity change. Ser69 GO was found in two
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different conformations: at a high distance and a low distance.
Cheng et al observed the low distance conformation only 10%
of the time, while Zamora et al found the opposite; the Ser69
GO is located within the coordination sphere (∼3Å) most of
the time but flips to a longer distance (∼6Å) outside the Ca2+
coordination sphere occasionally, where it can stay for ∼5% of
the time. Phosphorylation doubles the time spent at the long
distance, which may explain the Ca2+-sensitivity change upon
phosphorylation. The difference is ascribed by Zamora et al to
the shorter simulation times in the Cheng et al study that have
only sampled the longer distance state. In addition, it is thought
that the small box size used may result in periodic artifacts
mostly due to the L shaped configuration of the starting molecule
and the hinge motion that elongates the molecule, increasing
the probability of self-association. The study of Zamora et al
used real phosphorylation in Ser22 and 23 whereas the study of
Cheng et al used phosphomimetic mutations S23/S24D, although
there are no structural or physiological differences between the
effects of phosphorylation and phosphomimetic mutations in
the myofilament (Finley et al., 1999; Mamidi et al., 2012; Rao
et al., 2014). Using S23/24D allowed Cheng et al to make direct
comparisons between MD simulations and physiological data.
The contacts between the intrinsically disordered segments
and the troponin core are interesting since they are involved in
the mechanism of regulation by troponin (Cheng and Regnier,
2016). In order for the opening of the hydrophobic cleft upon
Ca2+ binding to occur, TnC must interact with the TnI switch
peptide (148–154). The N-terminal TnC-TnI (1–30) interaction
is also crucial for the phosphorylation signal to modulate Ca2+-
sensitivity. Finally, the disordered C-terminus of TnT (212–298),
which has not previously been simulated,maybe involved in these
interactions.
In their MD simulations, Cheng et al observed that
phosphorylation decreased the overall stability of troponin
as determined by RMSF plots and changed the interactions
between TnC and TnI. More specifically, they found
increased intrasubunit interactions between the N-terminal
and the inhibitory TnI peptide, which are not present in the
unphosphorylated structure. In contradiction to this study,
the study by Zamora et al showed that phosphorylation does
not affect overall stability of any part of the troponin complex
and that phosphorylation changes the interactions between
the intrinsically disordered segments and TnC. Moreover, the
C-terminus of TnT has proven to make a significant difference to
the analysis since it interacts with both TnC N-terminal domain
and the TnI N-terminal peptide.
In essence, Zamora’s analysis indicates that phosphorylation
never induces new interactions between the subunits but results
in a number of subtle changes in the dynamics of existing
interactions. A recent study supports this finding, as the TnI
mutation R145W causing restrictive cardiomyopathy reduces
the interaction frequencies between TnC and TnI leading to
blunting of the adrenergic response (Dvornikov et al., 2016).
However, contradictory results using peptides found that major
conformational changes occur upon phosphorylation (Heller
et al., 2003; Howarth et al., 2007). The fact that phosphorylation
causes only subtle structural changes is in accordance with the
fact that the Ca2+-sensitivity change upon phosphorylation is
only 2-fold. It is interesting that despite these subtle changes, the
physiological effect of phosphorylation is great.
Another exciting point arising from all these studies on
troponin is its potential to determine how mutations affect
troponin’s structure, Ca2+ binding and also the effect of
phosphorylation. Over 100 troponin mutations in cardiac
TnT, TnC, or TnI have been linked so far with genetic
cardiomyopathies. Different troponin mutations have different
effects on protein-protein interactions, crossbridge cycle, myosin
ATPase activity and phosphorylation levels of thin filament
proteins, but all mutations affect troponin Ca2+-sensitivity
(Marston, 2011; Lu et al., 2013). In a recent study it was observed
that mutations in troponin causing cardiomyopathies lead to a
decrease in the disorder score, reducing troponin’s flexibility (Na
et al., 2016).
Previous MD studies have been performed on how loss-of-
function and gain-of-function mutations affect Ca2+ binding
to troponin (Kekenes-Huskey et al., 2012; Lindert et al.,
2012). Cheng et al. tried to explain how mutations affect
phosphorylation changes using MD simulations in a study
comparing non-phosphorylated and S23/24D phosphomimetic
troponin containing the HCM mutations TnI R146G and R21C.
Both mutations increased Ca2+-sensitivity and blunted the effect
of phosphorylation, confirmed using biochemical methods. MD
simulations showed that both mutations increased the Ca2+
binding affinity, asmeasured by distance between Ca2+ and Ser69
GO and inhibited formation of intrasubunit interactions between
TnI N-terminus and inhibitory peptide in the phosphomimetic
mutants, which are normally seen in S23/S24D WT troponin
(Cheng et al., 2015). P83S mutation in the IT arm of TnI had
similar effects, although the blunting effect was “weaker” in MD
simulations (Cheng et al., 2016).
The same group studied the structural mechanism of TnI
R145G HCM mutation that also blunts TnI phosphorylation
(Regnier et al., 2014; Lindert et al., 2015). R145G increased the
interaction between Ca2+ and Ser69 GO explaining the increased
Ca2+ binding. On the other hand, these interactions were not
observed in Zamora’s analysis and the most evident effect of
the mutations TnI R145G (HCM), TnI K36Q, and TnC G159D
(both DCM) is that they trap Ser69 GO in the short distance
configuration (Sheehan et al., 2016; Zamora et al., 2016b).
The changes caused by mutations can be reversible, as we
recently discovered that Epigallocatechin-3-gallate (EGCG) and
related compounds could restore the Ca2+-sensitivity change
upon phosphorylation in DCM or HCM mutant thin filaments
that were originally uncoupled (Papadaki et al., 2015). The
molecular mechanism of action of EGCG is still to be elucidated,
although docking studies indicate EGCG is likely to bind at the
interface between N-terminus TnC and TnI (1–30). Current MD
studies provide a basis for the investigation of this recoupling
process (Hwang, 2016; Marston et al., 2016).
To address how troponin regulates muscle contractility it
is necessary to extend studies from isolated troponin to the
thin filament. Yang et al have made the most comprehensive
reconstruction of actin-tropomyosin-troponin in the absence
of Ca2+ at a resolution of 25Å and have located troponin on
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FIGURE 2 | Troponin rendering onto the thin filament. Thin filament is
represented by two coiled coil tropomyosin monomers shown in cyan and
blue, decorated by actin monomers shown in ribbon view in magenta.
Troponin’s electron density as determined by 3D reconstruction from cryo-EM
is represented in golden. Two troponin monomers are shown as they are
predicted to be located on the thin filament and the different regulatory regions
are indicated. Green arrow, N-terminus of TnT; light blue arrow, C-terminus of
TnI (dynamic region); dark blue line, N-terminal extension of TnI (dynamic
region); Orange circle, N-terminal domain of TnC; Red circle, C-terminal
domain of TnC. The 3D reconstruction coordinates were kindly supplied by Dr
William Lehman (Boston University, MA, USA) and the image was constructed
by Mr Juan Eiros Zamora (Imperial College London, UK).
the previously determined actin-tropomyosin, showing details
never observed before (Yang et al., 2014). Most strikingly, the
C-terminal inhibitory domain of TnI is orientated across the
filament, binding to actin close to the N-terminal TnT of the
troponin on the opposite side of the filament. The density
envelope corresponding to the core domain of troponin is
apparent and an attempt has been made to fit troponin into this;
the mobile parts of the molecule are, as expected, not seen but
the orientation of troponin core indicates that both the regulatory
Ca2+ binding site and the phosphorylatable serines of TnI would
be accessible to the solution (Figure 2).
Of course this is a static model of just one state; a fully
dynamic model of the thin filament is not yet accessible, although
progress is being made on several fronts. The dynamics of the
actin filament have been simulated using course-grainedmethods
(Fan et al., 2012; Saunders and Voth, 2012) and the structure
of tropomyosin alone and bound to actin has been simulated
by MD (Zheng et al., 2013). Manning et al have developed
the EM structures of the thin filament into a fully atomistic
model and derived structures for the whole filament by energy
minimization (Manning et al., 2011). This method seems capable
of reproducing the features of the Ca2+ switch and even to
explain how mutations like TnT R92Q that are remote from
troponin can change Ca2+-sensitivity by using MD simulations
of the whole thin filament (Williams et al., 2016). However,
current MD simulations are run for less than 5 ns and so do not
even start to explore the range of conformations possible in real
life.
CONCLUSIONS
In conclusion, troponin has a rather dynamic structure, owing
to the intrinsically disordered domains. This brings difficulties
in elucidating its exact structure and thus the mechanisms of
its regulation. Determining the structure of troponin mobile
regions will not only lead to understanding the changes that
occur upon its regulation, but also to predicting the effect of
a mutation or a pharmacological agent. For example, just by
knowing the structure of tropomyosin and its exact interactions
with actin it has been possible to predict the effect of disease-
causing mutations (Marston et al., 2013; Donkervoort et al.,
2015). With troponin it is not possible to make such predictions
at the moment, as the structure is still unresolved. However,
MD simulations may be the best way to study troponin, since
the molecule is treated as a moving object and not as a rigid
structure. Technical and mathematical advances give hope that
in the near future it will be possible to simulate an ensemble
of several million atoms for µs and thereby finally get a full
description of the dynamic regulated thin filament.
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